CORT
VENTE TOTALE: 26 685 titres (~3 270 169,36 $ US)
- Insiders
- Park Kimberly
- Total bought
- —
- Total sold
- $3,270,169
- Last activity
- 2026-08-26
- Last synced
-
2026-09-01 10:09:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-31
CORT presents a conflicted profile: while liquidity remains solid (score 85), the fundamental trend is deeply concerning with sharply contracting operating margins, rising EV/EBITDA multiples, and deteriorating ROIC…
The first sentence of the analysis written for CORT on 2026-08-31 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | |
| Ebit Margin | 8.7% | 23.9% | 25.8% | 28.9% | 34.2% | |
| Ebitda Margin | 9.0% | 24.1% | 26.0% | 29.2% | 35.0% | |
| Operating Profit Margin | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | |
| Pretax Profit Margin | 8.7% | 23.9% | 25.8% | 28.9% | 34.2% | |
| Continuous Operations Profit Margin | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | |
| Net Profit Margin | 13.1% | 20.7% | 22.0% | 25.2% | 30.7% | |
| Bottom Line Profit Margin | 12.9% | 20.7% | 21.9% | 25.2% | 30.7% | |
| Current Ratio | 2.923 | 3.350 | 4.389 | 6.887 | 5.605 | |
| Quick Ratio | 2.846 | 3.262 | 4.315 | 6.803 | 5.500 | |
| Solvency Ratio | 0.538 | 0.876 | 0.934 | 1.258 | 2.410 | |
| Cash Ratio | 0.726 | 0.907 | 1.297 | 0.915 | 1.633 | |
| Price To Earnings Ratio | 36.632 | 37.326 | 31.843 | 21.379 | 20.412 | |
| Price To Earnings Growth Ratio | -1.236 | 1.154 | 4.322 | -10.369 | 3.756 | |
| Forward Price To Earnings Growth Ratio | -1.236 | 1.154 | 4.322 | -10.369 | 3.756 | |
| Price To Earnings Diluted Ratio | 42.439 | 40.967 | 34.553 | 23.345 | 22.247 | |
| Price To Earnings Diluted Growth Ratio | -1.273 | 1.328 | 4.294 | -10.388 | 4.728 | |
| Price To Book Ratio | 5.579 | 7.654 | 6.638 | 4.322 | 6.093 | |
| Price To Sales Ratio | 4.747 | 7.706 | 6.973 | 5.397 | 6.257 | |
| Price To Free Cash Flow Ratio | 25.492 | 26.554 | 26.506 | 18.087 | 13.678 | |
| Price To Operating Cash Flow Ratio | 25.454 | 26.263 | 26.477 | 18.025 | 13.639 | |
| Debt To Assets Ratio | 0.007 | 0.008 | 0.000 | 0.002 | 0.001 | |
| Debt To Equity Ratio | 0.009 | 0.010 | 0.000 | 0.002 | 0.001 | |
| Debt To Capital Ratio | 0.009 | 0.010 | 0.000 | 0.002 | 0.001 | |
| Long Term Debt To Capital Ratio | 0.008 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.292 | 1.237 | 1.227 | 1.163 | 1.128 | |
| Working Capital Turnover Ratio | 2.342 | 1.971 | 1.235 | 1.245 | 1.126 | |
| Operating Cash Flow Ratio | 0.855 | 1.407 | 1.216 | 1.660 | 3.532 | |
| Operating Cash Flow Sales Ratio | 0.186 | 0.293 | 0.263 | 0.299 | 0.459 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.999 | 0.989 | 0.999 | 0.997 | 0.997 | |
| Debt Service Coverage Ratio | 0.000 | 171.948 | 709.815 | 89.831 | 219.504 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 238.923 | 841.318 | 105.269 | 319.186 | |
| Operating Cash Flow Coverage Ratio | 23.251 | 28.556 | 841.318 | 105.269 | 319.186 | |
| Capital Expenditure Coverage Ratio | 672.967 | 91.191 | 913.950 | 291.339 | 357.979 | |
| Dividend Paid And Capex Coverage Ratio | 672.967 | 91.191 | 913.950 | 291.339 | 357.979 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 51.205 | 31.205 | 25.703 | 17.911 | 17.294 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 98.3% | ▼-0.1% | ▼-0.2% |
| Ebit Margin | 8.7% | ▼-15.2% | ▼-15.6% |
| Ebitda Margin | 9.0% | ▼-15.1% | ▼-15.7% |
| Operating Profit Margin | 5.9% | ▼-14.4% | ▼-16.2% |
| Pretax Profit Margin | 8.7% | ▼-15.2% | ▼-15.6% |
| Continuous Operations Profit Margin | 13.1% | ▼-7.8% | ▼-9.3% |
| Net Profit Margin | 13.1% | ▼-7.6% | ▼-9.3% |
| Bottom Line Profit Margin | 12.9% | ▼-7.8% | ▼-9.4% |
| Current Ratio | 2.923 | ▼-0.427 | ▼-1.708 |
| Quick Ratio | 2.845 | ▼-0.416 | ▼-1.700 |
| Solvency Ratio | 0.538 | ▼-0.339 | ▼-0.666 |
| Cash Ratio | 0.726 | ▼-0.181 | ▼-0.370 |
| Price To Earnings Ratio | 36.632 | ▼-0.694 | ▲7.113 |
| Price To Earnings Growth Ratio | -1.236 | ▼-2.390 | ▼-0.761 |
| Forward Price To Earnings Growth Ratio | -1.236 | ▼-2.390 | ▼-0.761 |
| Price To Earnings Diluted Ratio | 42.439 | ▲1.472 | ▲9.729 |
| Price To Earnings Diluted Growth Ratio | -1.273 | ▼-2.601 | ▼-1.011 |
| Price To Book Ratio | 5.580 | ▼-2.075 | ▼-0.478 |
| Price To Sales Ratio | 4.747 | ▼-2.959 | ▼-1.469 |
| Price To Free Cash Flow Ratio | 25.492 | ▼-1.062 | ▲3.429 |
| Price To Operating Cash Flow Ratio | 25.454 | ▼-0.809 | ▲3.482 |
| Debt To Assets Ratio | 0.007 | ▼-0.001 | ▲0.004 |
| Debt To Equity Ratio | 0.009 | ▼-0.001 | ▲0.005 |
| Debt To Capital Ratio | 0.009 | ▼-0.001 | ▲0.005 |
| Long Term Debt To Capital Ratio | 0.008 | ▲0.008 | ▲0.006 |
| Financial Leverage Ratio | 1.292 | ▲0.055 | ▲0.083 |
| Working Capital Turnover Ratio | 2.342 | ▲0.371 | ▲0.758 |
| Operating Cash Flow Ratio | 0.855 | ▼-0.552 | ▼-0.879 |
| Operating Cash Flow Sales Ratio | 0.186 | ▼-0.107 | ▼-0.114 |
| Free Cash Flow Operating Cash Flow Ratio | 0.999 | ▲0.009 | ▲0.003 |
| Debt Service Coverage Ratio | 0.000 | ▼-171.948 | ▼-238.220 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-238.923 | ▼-300.939 |
| Operating Cash Flow Coverage Ratio | 23.251 | ▼-5.305 | ▼-240.265 |
| Capital Expenditure Coverage Ratio | 672.967 | ▲581.776 | ▲207.482 |
| Dividend Paid And Capex Coverage Ratio | 672.967 | ▲581.776 | ▲207.482 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 51.205 | ▲20.000 | ▲22.541 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.61B | $5.20B | $3.36B | $2.17B | $2.29B | |
| Enterprise value | $3.50B | $5.08B | $3.23B | $2.10B | $2.21B | |
| EV / Sales | 4.60x | 7.53x | 6.69x | 5.24x | 6.05x | |
| EV / Op. cash flow | 24.65x | 25.65x | 25.41x | 17.48x | 13.18x | |
| EV / Free cash flow | 24.68x | 25.94x | 25.44x | 17.54x | 13.22x | |
| EV / EBITDA | 51.20x | 31.20x | 25.70x | 17.91x | 17.29x | |
| Net debt / EBITDA | -1.67x | -0.74x | -1.08x | -0.56x | -0.60x | |
| Current ratio | 2.92x | 3.35x | 4.39x | 6.89x | 5.61x | |
| Income quality | 1.45x | 1.40x | 1.20x | 1.19x | 1.49x | |
| Graham number | $12 | $14 | $11 | $10 | $8 | |
| Graham net-net | $2 | $3 | $3 | $4 | $2 | |
| Tax burden | 149.9% | 86.5% | 85.2% | 87.3% | 90.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $319.4M | $330.8M | $354.1M | $426.8M | $218.9M | |
| Invested capital | $325.9M | $338.8M | $354.4M | $428.5M | $220.4M | |
| Return on assets | 11.9% | 16.6% | 17.1% | 17.4% | 26.6% | |
| Operating ROA | 5.3% | 18.7% | 17.8% | 22.4% | 25.0% | |
| Return on tangible assets | 11.9% | 16.6% | 17.1% | 17.4% | 26.6% | |
| Return on equity | 15.4% | 20.6% | 20.9% | 20.2% | 29.9% | |
| Return on invested capital | 6.7% | 17.1% | 17.7% | 19.2% | 29.7% | |
| Return on capital employed | 6.7% | 19.6% | 20.8% | 22.0% | 33.1% | |
| Earnings yield | 2.8% | 2.7% | 3.2% | 4.7% | 4.9% | |
| Free cash flow yield | 3.9% | 3.8% | 3.8% | 5.5% | 7.3% | |
| Capex / Op. cash flow | 0.1% | 1.1% | 0.1% | 0.3% | 0.3% | |
| Capex / Depreciation | 11.2% | 162.6% | 5.9% | 12.0% | 15.3% | |
| Capex / Sales | 0.0% | 0.3% | 0.0% | 0.1% | 0.1% | |
| SG&A / Sales | 58.9% | 41.5% | 38.2% | 38.0% | 33.4% | |
| R&D / Sales | 33.5% | 36.6% | 38.2% | 32.6% | 31.1% | |
| Stock comp / Sales | 11.1% | 9.1% | 10.1% | 10.6% | 11.7% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 29d | 31d | 43d | 43d | 29d | |
| Days payables outstanding | 1138d | 516d | 980d | 812d | 477d | |
| Operating cycle | 391d | 448d | 478d | 456d | 374d | |
| Cash conversion cycle | -747d | -68d | -501d | -356d | -104d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-30.5%EV / Sales ▼-38.9%EV / EBITDA ▲+64.1%EV / Op. cash flow ▼-1.005Earnings yield ▲+0.001Graham number ▼-2.556
Profitability
Return on equity ▼-0.052Return on assets ▼-0.047Return on invested capital ▼-0.104Return on capital employed ▼-0.129Operating ROA ▼-0.134Income quality ▲+0.044Tax burden ▲+0.634
Efficiency
Days sales outstanding ▼-2.742Days payables outstanding ▲+621.820Operating cycle ▼-57.127Cash conversion cycle ▼-678.946Capex / Sales ▼-0.003R&D / Sales ▼-0.031
Balance-sheet strength
Current ratio ▼-0.427Net debt / EBITDA ▼-0.932Working capital ▼-11450000.000Invested capital ▼-12990000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+57.8%EV / Sales ▼-24.0%EV / EBITDA ▲+196.1%EV / Op. cash flow ▲+11.469Earnings yield ▼-0.022Graham number ▲+3.170
Profitability
Return on equity ▼-0.146Return on assets ▼-0.146Return on invested capital ▼-0.231Return on capital employed ▼-0.264Operating ROA ▼-0.197Income quality ▼-0.046Tax burden ▲+0.599
Efficiency
Days sales outstanding ▼-0.287Days payables outstanding ▲+660.104Operating cycle ▲+16.898Cash conversion cycle ▼-643.207Capex / Sales ▼-0.001R&D / Sales ▲+0.024
Balance-sheet strength
Current ratio ▼-2.682Net debt / EBITDA ▼-1.071Working capital ▲+100457000.000Invested capital ▲+105414000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-29 Bank of America Corp DE Grows Holdings in Corcept Therapeutics Incorporated $CORT Bank of America Corp DE raised its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 33.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 111,736 shares of the biotechnology company''s stock after acquiring an additional 28,078 shares during the period. Bank
- 2026-08-28 Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report? Corcept (CORT) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-28 Bank of New York Mellon Corp Invests $49.19 Million in Corcept Therapeutics Incorporated $CORT Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 565,666 shares of the biotechnology company''s stock, valued at approximately $49,185,000. Bank of New York Mellon Corp owned approximately
- 2026-08-22 BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT BlackRock Inc. bought a new stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,432,023 shares of the biotechnology company''s stock, valued at approximately $1,080,964,000. BlackRock Inc. owned about 11.50% of
- 2026-08-21 Like The Knick''s, Corcept Rebounded And Is Crushing It Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli''s rapid launch for platinum-resistant ovarian cancer and Korlym''s resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.
- 2026-08-18 Mega Cap Growth vs Small Cap Growth: Which ETF Wins? MGK offers lower costs and mega-cap stability; SLYG delivered 27.4% returns over one year with broader diversification across industrials and healthcare.
- 2026-08-18 Trump is up 230% on this stock trade since March President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.
- 2026-08-16 Handelsbanken Fonder AB Boosts Stock Holdings in Corcept Therapeutics Incorporated $CORT Handelsbanken Fonder AB grew its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 28.1% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 36,881 shares of the biotechnology company''s stock after purchasing an additional 8,100 shares during the quarter. Handelsbanken Fonder
- 2026-08-05 Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 2026-08-05 Raised Guidance Lifts Corcept to 52-Week High CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing''s syndrome.